AI assistant
Sending…
Insight Molecular Diagnostics Inc. — Director's Dealing 2020
Dec 15, 2020
34238_dirs_2020-12-15_24dabc1a-7d5c-4640-b7ee-00899e9ba49d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2020-12-11
Reporting Person: Ross Douglas T. (CMO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-12-11 | Common Stock | A | 5317 | — | Acquired | 5317 | Direct |
Footnotes
F1: The shares of the Issuer's common stock were issued to the Reporting Person for the repayment of deferred compensation in lieu of cash at a price of $2.07 per share.
More from Insight Molecular Diagnostics Inc.
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 12
Major Shareholding Notification
2026
Feb 12
Regulatory Filings
2026
Feb 12
Regulatory Filings
2026
Feb 11
Regulatory Filings
2026
Feb 11
Director's Dealing
2025
Nov 13
Interim / Quarterly Report
2025
Nov 10